Medistim ASA (OSL:MEDI)
Norway
· Delayed Price · Currency is NOK | Market Cap | 4.26B |
| Revenue (ttm) | 699.77M |
| Net Income (ttm) | 159.21M |
| Shares Out | 18.29M |
| EPS (ttm) | 8.71 |
| PE Ratio | 26.75 |
| Forward PE | 27.44 |
| Dividend | 8.00 (3.43%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 6,432 |
| Average Volume | 21,162 |
| Open | 232.00 |
| Previous Close | 233.00 |
| Day's Range | 230.00 - 234.00 |
| 52-Week Range | 157.00 - 292.00 |
| Beta | 1.02 |
| RSI | 55.49 |
| Earnings Date | Apr 14, 2026 |
About Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplan... [Read more]
Financial Performance
In 2025, Medistim ASA's revenue was 699.77 million, an increase of 24.38% compared to the previous year's 562.60 million. Earnings were 159.21 million, an increase of 53.33%.
Financial StatementsNews
Medistim ASA (STU:MD1) Q4 2025 Earnings Call Highlights: Record Sales and Strategic Expansion ...
Medistim ASA (STU:MD1) Q4 2025 Earnings Call Highlights: Record Sales and Strategic Expansion Amid Regional Challenges
Q4 2025 Medistim ASA Earnings Call Transcript
Q4 2025 Medistim ASA Earnings Call Transcript
Medistim ASA Earnings Call Transcript: Q4 2025
Record sales and profit in 2025, with strong growth in Americas and imaging products. U.S. tariffs offset by price increases, and a direct office opened in Japan to drive further expansion. Dividend of NOK 8 per share proposed.
Medistim ASA (FRA:MD1) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Regional ...
Medistim ASA (FRA:MD1) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Regional Performance Insights
Q3 2025 Medistim ASA Earnings Call Transcript
Q3 2025 Medistim ASA Earnings Call Transcript
Medistim ASA Earnings Call Transcript: Q3 2025
Record Q3 and year-to-date results with strong revenue and profit growth, led by Americas and Asia-Pacific. Imaging and cardiac products showed robust performance, while EMEA lagged due to high market penetration. Outlook remains positive, with focus on U.S., China, and vascular segment expansion.
Medistim ASA Earnings Call Transcript: Q2 2025
Second quarter and first half 2025 saw record sales and profit growth, led by strong performance in the Americas and Asia Pacific, improved gross margins, and a robust product mix. Outlook is positive with expected benefits from new software launches and price increases.
Medistim ASA Earnings Call Transcript: Q1 2025
Q1 2025 saw record revenue and EBIT, with all regions and product lines contributing to strong growth. Gross margin and EPS improved significantly, and the launch of the INTUI platform is expected to drive further gains. Dividend and share buyback programs were executed.
Medistim ASA (STU:MD1) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Innovations ...
Medistim ASA (STU:MD1) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Innovations Amid Regional Challenges
Q4 2024 Medistim ASA Earnings Call Transcript
Q4 2024 Medistim ASA Earnings Call Transcript
Medistim ASA Earnings Call Transcript: Q4 2024
Record Q4 sales and strong full-year growth driven by Americas and EMEA offset APAC weakness. EBIT and profit after tax were stable, with improved gross margin and a proposed higher dividend. Launch of INTUI software and new clinical studies support a positive 2025 outlook.
Medistim ASA Transcript: CMD 2024
Accelerated growth is expected through innovation, expanded direct market coverage, and the launch of the INTUI software platform, which modernizes surgical workflows and reporting. Clinical studies and new business models support broader adoption, while financial guidance targets NOK 1 billion in annual sales within a few years.
Medistim ASA (FRA:MD1) Q3 2024 Earnings Call Highlights: Strong Sales Growth in Americas Amid ...
Medistim ASA (FRA:MD1) Q3 2024 Earnings Call Highlights: Strong Sales Growth in Americas Amid EBIT Challenges
Q3 2024 Medistim ASA Earnings Call Transcript
Q3 2024 Medistim ASA Earnings Call Transcript
Medistim ASA Earnings Call Transcript: Q3 2024
Q3 saw 7% sales growth in NOK, led by Americas' strong recovery, while EMEA and APAC declined for the quarter but EMEA remains up year-to-date. EBIT margin normalized at 24%, with higher costs from new direct operations and increased R&D spend. Vascular and flow products drove growth, while imaging sales lagged.
Medistim ASA Earnings Call Transcript: Q2 2024
Record Q2 sales and a strong EBIT margin recovery highlight robust performance, with EMEA leading growth and third-party products supporting revenue. Direct market expansion and inventory normalization are expected to further improve margins and cash flow.